Cefpodoxime proxetil

Edina Avdic, Pharm.D., BCPS, Paul A. Pham, Pharm.D.

INDICATIONS

Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) [3]
Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae

Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first[1].

There's more to see -- the rest of this topic is available only to subscribers.

All content is protected by copyright and may not be used for AI model training or other unauthorized purposes.